UPDATE - Richter and Forest Laboratories announce positive trial results of drug for bipolar mania
Hungarian drug company Gedeon Richter and US partner Forest Laboratories said on Wednesday that the preliminary top-line results of Phase III trials of a new antipsychotic agent Cariprazine (RGH-188) for the treatment of patients with acute mania associated with bipolar I disorder have been positive.
In terms of the Young Mania Rating Scale (YMRS), a primary endpoint for the testing, patients suffering from acute mania treated with Cariprazine showed significant improvement in symptoms compared to placebo-treated patients beginning already on the fourth day of treatment, the drug companies said.
Analysis of data will be completed over the coming weeks.
Clinical trials of Cariprazine for the treatment of schizophrenia and bipolar depression are ongoing, and use of the agent in the supplementary treatment of major depressive-disorder is also being examined.
“These exciting positive Phase III results in patients with bipolar mania demonstrate the potential of cariprazine as a novel antipsychotic agent,” said Marco Taglietti, MD., Senior Vice President of Research and Development and President, Forest Research Institute. “We will continue to investigate the therapeutic benefits of this novel dual acting D3/D2 compound across other CNS disorders as well.”
"These data together with those of the Phase II program prove that cariprazine provides a clinically meaningful improvement with good tolerability in patients with acute mania associated with bipolar I disorder. It also confirms, the D3/D2 partial agonist research concept elaborated by Richter’s researchers was a valuable and novel approach,” commented Richter Research Director Zsolt Szombathelyi.
ADVERTISEMENT
Number of Liquidations Increasing Rapidly
Orbán's Salary Increased to HUF 4.178 mln
Hungary Tops out HUF 300bn Munitions Complex
Around 2,800 Events Take Place in European Capital of Cultur...
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
